GlassScriptPhysician profile
Roger G Levine
NPI 1245241181
$8,308.31
in general payments reported to CMS, 2019-2025
23 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,644 · 2020: $1,108 · 2021: $2,097 · 2022: $1,623 · 2023: $1,323 · 2024: $391 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,310.26 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $994.35 | 2019-2024 | Spravato, Invega, Invega Sustenna |
| Lundbeck LLC | $922.99 | 2019-2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $891.84 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $807.12 | 2021-2023 | |
| Alkermes, INC. | $782.39 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $572.82 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Sunovion Pharmaceuticals INC. | $391.13 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $313.63 | 2019-2023 | Hetlioz, Fanapt |
| Bausch Health US, LLC | $220.20 | 2021-2023 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $215.90 | 2021-2022 | |
| Axsome Therapeutics, INC. | $196.43 | 2022-2024 | Auvelity |
| Allergan, INC. | $179.34 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.92 | 2020-2023 | Caplyta |
| Indivior INC. | $93.34 | 2019-2023 | Perseris |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $86.52 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $73.69 | 2019 | |
| Shire North American Group INC | $50.74 | 2019 | |
| Corium, LLC | $24.24 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $24.09 | 2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $16.68 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $13.88 | 2021 | |
| Neuronetics, INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.